Recent Company News

• 03:05 AM ET May 13, 2025
  

  Cantor Fitzgerald transfers ALKS, ATAI, AXSM, others

• 09:16 AM ET May 08, 2025
  

  StreetAccount Summary - US Pre-market trading update

• 06:41 AM ET May 08, 2025
  

  Compass Pathways reports Q1 EPS ($0.24) vs year-ago ($0.55) ($3.74, 0.00)

• 06:33 AM ET Apr 29, 2025
  

  Compass Pathways establishes strategic collaboration with HealthPort to inform the potential delivery of COMP360 synthesized psilocybin treatment in underserved communities ($3.88, 0.00)

• 06:01 AM ET Apr 22, 2025
  

  Compass Pathways announces dosing complete for all participants in Part A of Phase 3 COMP005 trial of COMP360 psilocybin for treatment-resistant depression ($3.38, 0.00)

• 10:18 AM ET Apr 07, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (1167 total)

• 10:10 AM ET Apr 04, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (1064 total)

• 05:00 PM ET Apr 02, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 10:08 AM ET Mar 31, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (465 total)

• 06:31 AM ET Mar 26, 2025
  

  Compass Pathways completes recruitment for Phase 3 COMP005 trial of COMP360 psilocybin for treatment-resistant depression ($3.07, 0.00)